| ARGENX SE EO -,10 |
| Niederlande |
| Gesundheit |
| NL0010832176 / A11602 |
| 1AE (Frankfurt) |
| FRA:1AE, ETR:1AE, 1AE:GR |
| EuroStoxx50 |
| https://www.argenx.com/ |
|
argenx SE is a commercial-stage, global, fully-integrated biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in the development of differentiated antibody-based therapies for severe autoimmune diseases. The company levera..
>Volltext.. |
| 45518.37 Mio. EUR |
| 41041.34 Mio. EUR |
| 4422.6 Mio. EUR |
| 1301.74 Mio. EUR |
| 1451.63 Mio. EUR |
| 23.49 EUR |
| 40.58 Mio. EUR |
| 3094.45 Mio. EUR |
| 960.57 Mio. EUR |
| 3.29 |
| 59.81% |
| 24.69% |
| - |
| - |
| - |
| - |
| ARGENX, ARGEN-X, ARGEN X |
| 17.08.26 |
|